PLCB1 and acute myeloid leukemia: The other dataset GSE111085 revealed that patients whose illness transformed to AML within 12 months (sAML) had higher expression levels of PLCB1 than those whose disease remained stable MDS (p = 0.006) (Fig. 4G).